Bifidobacterium lactis inhibits NF-κB in intestinal epithelial cells and prevents acute colitis and colitis-associated colon cancer in mice
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The aim of this study was to investigate the antiinflammatory effects of Bifidobacterium lactis on intestinal epithelial cells (IECs) and on experimental acute murine colitis and its tumor prevention effects on colitis-associated cancer (CAC) in mice. METHODS: Human HT-29 cells were stimulated with IL-1beta, lipopolysaccharides, or tumor necrosis factor-alpha with and without B. lactis, and the effects of B. lactis on nuclear factor kappa B (NF-kappaB) signaling in IEC were examined. For in vivo study, dextran sulfate sodium (DSS)-treated mice were fed with and without B. lactis. Finally, we induced colonic tumors in mice by azoxymethane (AOM) and DSS and evaluated the effects of B. lactis on tumor growth. RESULTS: B. lactis significantly suppressed NF-kappaB activation, including NF-kappaB-binding activity and NF-kappaB-dependent reporter gene expression in a dose-dependent manner, and suppressed IkappaB-alpha degradation, which correlated with the downregulation of NF-kappaB-dependent gene products. Moreover, B. lactis suppressed the development of acute colitis in mice. Compared with the DSS group, the severity of DSS-induced colitis as assessed by disease activity index, colon length, and histological score was reduced in the B. lactis-treated group. In the CAC model, the mean number and size of tumors in the B. lactis-treated group were significantly lower than those in the AOM group. CONCLUSIONS: Our data demonstrate that B. lactis inhibits NF-kappaB and NF-kappaB-regulated genes in IEC and prevents acute colitis and CAC in mice. These results suggest that B. lactis could be a potential preventive agent for CAC as well as a therapeutic agent for inflammatory bowel disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB regulation in the immune system
Li, Q., & Verma, I. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri910 · Cited by 4,007
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Self-citationProtective role of probiotics and prebiotics in colon cancer
Wollowski, I., Rechkemmer, G., & Pool-Zobel, B. L. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/73.2.451s · Cited by 560 · cited 1×
“Such properties may be useful for both immunomodulatory and cancer prevention strategies.(15) Manipulation of intestinal bacterial flora has been used as”
BackgroundAnti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-κB activation
Riedel, C. U. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i23.3729 · Cited by 210
Cited by
Intestinal Inflammation and Cancer
Ullman, T. A., & Itzkowitz, S. H. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.057 · Cited by 1,119
Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy
Górska, A., Przystupski, D., Niemczura, M. J., & Kulbacka, J. (2019) · Current Microbiology · doi:10.1007/s00284-019-01679-8 · Cited by 344
Jakubczyk, D., Leszczyńska, K., & Górska, S. (2020) · Nutrients · doi:10.3390/nu12071973 · Cited by 311
Modulatory Effects of Probiotics During Pathogenic Infections With Emphasis on Immune Regulation
Raheem, A., Liang, L., Zhang, G., & Cui, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616713 · Cited by 302
Microbiome, inflammation and colorectal cancer
Chen, J., Pitmon, E., & Wang, K. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.006 · Cited by 265
Metadata
- Authors
- Kim, S. W., Kim, H. M., Yang, K. M., Kim, S.-A., Kim, S.-K., An, M. J., Park, J. J., Lee, S. K., Kim, T. I., Kim, W. H., & Cheon, J. H.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-09
- Volume
- 16
- Issue
- 9
- Pages
- 1514-1525
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2046191228
- Cited by
- 105
- References
- 4
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.